New Indian Biomanufacturing Hub Forms
A new global innovation campus focused on biomanufacturing and health tech is being established in Tirupati, India. The project is an MoU between IIT Tirupati, IISER Tirupati, and Canada's Dalhousie University. The campus will also concentrate on AI, digital systems, and clean energy, creating a new hub for life sciences R&D.
This partnership aligns with India's national BioE3 (Biotechnology for Economy, Environment, and Employment) Policy, a framework designed to make the country a global biomanufacturing leader and grow its bioeconomy to $300 billion by 2030. The policy focuses on developing a circular bioeconomy and creating shared infrastructure to help startups and academic labs scale up from pilot to pre-commercial production. Dalhousie University brings specific GMP (Good Manufacturing Practices) expertise, currently establishing GMP BioLabs East, a specialized research and biomanufacturing facility in Atlantic Canada designed to translate medical discoveries into clinical-grade therapies. This initiative is part of a broader Canadian effort to build a seamless drug development pipeline, with Dalhousie also involved in Canada's Immuno-engineering and Biomanufacturing Hub. The collaboration enters a booming Indian Contract Development and Manufacturing Organization (CDMO) market, which was valued at over USD 17.5 billion in 2024 and is projected to grow at a CAGR of more than 13% to reach over USD 37 billion by 2030. India possesses the highest number of US FDA-approved manufacturing facilities outside of the United States, positioning it as a key alternative for global pharma supply chains.
